Displaying drugs 426 - 450 of 8037 in total
Flutamide
An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Approved
Investigational
Trofinetide
Trofinetide is a novel synthetic analog of glypromate, also known as glycine–proline–glutamate (GPE), a naturally occurring protein in the brain and the N-terminal tripeptide of insulin-like growth factor 1 (IGF-1). Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked...
Approved
Investigational
Matched Description: … Trofinetide is a novel synthetic analog of [glypromate], also known as glycine–proline–glutamate (GPE ... [A258438] Trofinetide is believed to work by reducing inflammation and apoptosis of neurons. ... [A258438] Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[ …
Mirvetuximab soravtansine
Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide linker to the genotoxic compound DM4 (also known as soravtansine or ravtansine).[A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1....
Approved
Investigational
Matched Description: … on the surface of epithelial tumor cells, characteristic of ovarian, endometrial, triple-negative breast ... [A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1. ... [A254387]
The antibody component of mirvetuximab soravtansine-gynx binds to FRα, a receptor overexpressed …
Estradiol acetate
Estradiol acetate is a pro-drug ester of DB00783, a naturally occurring hormone that circulates endogenously within the human body. Estradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex hormone. As a pro-drug of estradiol, estradiol acetate therefore has the same downstream...
Approved
Investigational
Vet approved
Matched Description: … 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. ... Ester pro-drugs of estradiol are therefore considered to be bioidentical forms of estrogen [T84]. ... Administration of synthetic and bioidentical forms of estrogen, such as estradiol acetate, has shown …
Zilucoplan
Zilucoplan is a 15 amino-acid, synthetic macrocyclic peptide. It is a complement inhibitor that works to prevent the activation of C5, which is a complement protein involved in the innate immune system to initiate inflammatory responses. On October 17, 2023, zilucoplan gained its first FDA approval for the treatment of...
Approved
Matched Description: … It is a complement inhibitor that works to prevent the activation of C5, which is a complement protein ... [A261841] On October 17, 2023, zilucoplan gained its first FDA approval for the treatment of generalized …
Cyproheptadine
Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome.
Approved
Matched Description: … Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. ... perhaps more notable for its use in appetite stimulation[L32519] and its off-label use in the treatment of …
Olopatadine
Olopatadine is a selective histamine H1 antagonist and mast cell stabilizer that works by attenuating inflammatory and allergic reactions. It is a structural analog of doxepin, which has a minimal anti-allergic activity. Olopatadine works by blocking the effects of histamine, which is a primary inflammatory mediator that causes inflammatory and...
Approved
Matched Description: … An ophthalmic solution of olopatadine was approved by the FDA and European Union for the treatment of ... It is a structural analog of [doxepin], which has a minimal anti-allergic activity. ... [L6790] Olopatadine works by blocking the effects of histamine, which is a primary inflammatory mediator …
Bimatoprost
Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as...
Approved
Investigational
Matched Description: … are synthetic structural analogs of prostaglandin. ... Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which …
Linagliptin
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding . Linagliptin was approved by...
Approved
Matched Description: … Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes …
Butylscopolamine
Butylscopolamine is a peripherally acting antimuscarinic, anticholinergic agent. It is used to treat pain and discomfort caused by abdominal cramps, menstrual cramps, or other spasmodic activity in the digestive system. It is also effective at preventing bladder spasms. It is not a pain medication in the normal sense, since it...
Approved
Investigational
Vet approved
Matched Description: … It is on the WHO Model List of Essential Medicines, the most important medications needed in a basic …
Oseltamivir
Oseltamivir (marketed as the product TamifluⓇ), is an antiviral neuraminidase inhibitor used for the treatment and prophylaxis of infection with influenza viruses A (including pandemic H1N1) and B. Oseltamivir exerts its antiviral activity by inhibiting the activity of the viral neuraminidase enzyme found on the surface of the virus, which...
Approved
Matched Description: … The clinical benefit of use of oseltamivir is greatest when administered within 48 hours of the onset ... use of oseltamivir. ... [L7264]
The benefits of oseltamivir use are controversial; a 2014 Cochrane Review of the evidence …
Hydrocortisone
Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952.
Approved
Vet approved
Matched Categories: … Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use …
Hydroxyprogesterone caproate
Hydroxyprogesterone caproate is a synthetic steroid hormone that is similar to medroxyprogesterone acetate and megestrol acetate. It is an ester derivative of 17α-hydroxyprogesterone formed from caproic acid (hexanoic acid). Hydroxyprogesterone caproate was previously marketed under the trade name Delalutin by Squibb, which was approved by the U.S. Food and Drug...
Approved
Investigational
Matched Description: … It is an ester derivative of 17α-hydroxyprogesterone formed from caproic acid (hexanoic acid). ... preterm delivery in women with a history of preterm delivery, sparking a pricing controversy. ... approved Makena from KV Pharmaceutical (previously named as Gestiva) on February 4, 2011 for prevention of …
Acetylcysteine
Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose.[L31378,L31383,L31388,L31478] Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.[A228158,A228163,A228168]
Acetylcysteine was granted FDA approval on 14 September 1963.
Approved
Investigational
Matched Description: … Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of ... [L31378,L31383,L31388,L31478] Acetylcysteine has also been studied for a wide variety of off-label indications …
Ertapenem
Ertapenem is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics. It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to...
Approved
Investigational
Matched Description: … [A447] Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic …
Riluzole
A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi.
Approved
Investigational
Matched Description: … antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of …
Repaglinide
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood...
Approved
Investigational
Matched Description: … be lower than that of sulfonylureas since their action is dependent on the presence of glucose. ... the last 8-10 weeks of glucose control. ... cells of the pancreas to stimulate insulin release. …
Zopiclone
Zopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors. In addition to zopiclone's benzodiazepine pharmacological properties it also has some barbiturate-like properties.
Approved
Matched Description: … Zopiclone is a novel hypnotic agent used in the treatment of insomnia. ... Its mechanism of action is based on modulating benzodiazepine receptors. …
Parathyroid hormone
Parathyroid hormone (PTH) is a single-chain polypeptide composed of 84 amino acids. Available as Preotact, it is an identical form of human recombinant hormome which produced as a fusion protein undergoeing post-translational processing involving the cleavage of the OmpA leader sequence, leaving the mature protein as a single-chain 84 amino-acids...
Approved
Investigational
Matched Description: … Preotact is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic ... Parathyroid hormone (PTH) is a single-chain polypeptide composed of 84 amino acids. ... Available as Preotact, it is an identical form of human recombinant hormome which produced as a fusion …
Ethotoin
Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread...
Approved
Matched Description: … The mechanism of action is probably very similar to that of phenytoin. ... seizure activity rather than to abolish the primary focus of seizure discharges. ... drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of …
Tildrakizumab
Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis .
The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy...
Approved
Investigational
Matched Description: … The approved recommended dosage of ILUMYA is a subcutaneous injection of 100 mg at Weeks 0, 4, and every ... A study was performed on the pharmacokinetics of this drug on various ethnicities. ... high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of …
Ripretinib
Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as sunitinib and imatinib. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020....
Approved
Matched Description: … treatment with a minimum of 3 other kinase inhibitors. ... Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST ... [L13769]
It is the first drug approved as a fourth-line therapy in the specific setting of prior …
Clavulanic acid
Clavulanic acid is a beta-lactamase inhibitor that is frequently combined with Amoxicillin or Ticarcillin to fight antibiotic resistance by preventing their degradation by beta-lactamase enzymes, broadening their spectrum of susceptible bacterial infections. Clavulanic acid is derived from the organism Streptomyces clavuligerus. When it is combined with amoxicillin, clavulanic acid is...
Approved
Vet approved
Matched Description: … antibiotic resistance by preventing their degradation by beta-lactamase enzymes, broadening their spectrum of …
Osimertinib
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing...
Approved
Matched Description: … due to the presence of specific activating EGFR mutations within the tumour cells. ... [A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC ... Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs …
Givosiran
Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic...
Approved
Investigational
Matched Description: … patisiran]), a new class of drugs promising an important and exciting step forward in the treatment of ... Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of ... [L10202] Givosiran represents an important step forward in the treatment of acute hepatic porphyria as …
Displaying drugs 426 - 450 of 8037 in total